Randomized trial analysis demonstrates reduced mortality with microaxial flow pumps in infarct-related cardiogenic shock, highlighting the critical role of selective patient criteria.
To the Editor: The Danish–German Cardiogenic Shock (DanGer Shock) trial conducted by Møller et al. (April 18 issue) 1 showed a reduction in all-cause mortality with the use of a microaxial flow pump in a highly selected group of patients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock who had a minimal risk of possible hypoxic brain injury. The results are in contrast to those of previous randomized trials of mechanical circulatory support that evaluated intraaortic balloon pumps (IABPs), venoarterial extracorporeal membrane oxygenation, or microaxial flow pumps in this patient population. 2-5 These differences may (possibly) be explained by patient selection . . .
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: